0.21

FILE 'HOME' ENTERED AT 15:18:05 ON 23 OCT 2006

=> file biosis medline caplus wpids uspatfull COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 15:18:43 ON 23 OCT 2006 Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:18:43 ON 23 OCT 2006

FILE 'CAPLUS' ENTERED AT 15:18:43 ON 23 OCT 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:18:43 ON 23 OCT 2006 COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 15:18:43 ON 23 OCT 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s (substrate or support) and polymer
L1 482170 (SUBSTRATE OR SUPPORT) AND POLYMER

=> s ll and acrylamide(10a) 40 L2 1134 Ll AND ACRYLAMIDE(10A) 40

=> s 12 and 40% L3 1134 L2 AND 40%

=> s 13 and 40% (5a) acrylamide L4 721 L3 AND 40% (5A) ACRYLAMIDE

=> s 14 and reactive grup? L5 0 L4 AND REACTIVE GRUP?

=> s 14 and reactive group? L6 86 L4 AND REACTIVE GROUP?

=> s 16 and biomolecule L7 13 L6 AND BIOMOLECULE

=> s 17 and covalent L8 11 L7 AND COVALENT

=> dup rem 18
PROCESSING COMPLETED FOR L8
L9 10 DUP REM L8 (1 DUPLICATE REMOVED)

=> d 19 bib abs 1-10

L9 ANSWER 1 OF 10 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN DUPLICATE 1

AN 2005-283756 [29] WPIDS

DNC C2005-088137 [29] DNN N2005-232660 [29]

TI Substrate, useful for immobilizing biomolecules such as nucleic acids and proteins, comprises a surface and a polymer that coats at least a portion of and being coupled to the surface

```
DC
     A14; A96; B04; D16; P32; P73
     OFSTEAD R F; SWAN D G; SWANSON M J; OFSTEAD R; SWAN D; SWANSON M
PA
     (SURM-N) SURMODICS INC
CYC
    107
PIA US 20050074478 A1 20050407 (200529)* EN
                                               23[1]
     WO 2005033158 A2 20050414 (200529) EN
     EP 1668050
                    A2 20060614 (200641)
                                          EN
                    A1 20050414 (200656) EN
     AU 2004278408
    US 20050074478 A1 US 2003-677022 20031001; EP 1668050 A2 EP 2004-789464
     20040930; WO 2005033158 A2 WO 2004-US32443 20040930; EP 1668050 A2 WO
     2004-US32443 20040930; AU 2004278408 A1 AU 2004-278408 20040930
    EP 1668050
                     A2 Based on WO 2005033158
                                                A; AU 2004278408
                                                                    Al Based on
     WO 2005033158
PRAI US 2003-677022 20031001
     2005-283756 [29]
                        WPIDS
AΒ
     US 20050074478 A1
                         UPAB: 20051222
     NOVELTY - Substrate (I) comprises a surface (A) and a
     polymer (II) (comprising at least about 40 mol-%
     N-substituted acrylamide, N,N-disubstituted acrylamide
     , N-substituted methacrylamide and/or N,N-disubstituted methacrylamide;
     one or more pendant reactive groups configured to form
     covalent bond with biomolecule), which coats at least a
     portion of and being coupled to (A).
            DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
            (1) a composition (D) comprising (II);
            (2) a method of attaching biomolecule to surface of (A)
     comprising providing (D) (where (II) is configured to be covalently
     attached to the surface coating and immobilizing (D) on the
     substrate surface); providing solution comprising
     biomolecule comprising one or more functional groups reactive with
     the reactive groups; applying an aliquot of the
     solution to the substrate surface; and forming covalent
     bonds between the reactive group and the functional
     group of the biomolecule; and
            (3) a micro array comprising support surface; (II) (
     biomolecule covalently bound to the polymer in discrete
     spots) covalently coupled to the support surface.
            USE - (I) is useful for immobilizing biomolecules such as nucleic
     acids and proteins.
            ADVANTAGE - (I) is an improved form that provides a higher density
     of spots, retains sufficient hydrophilic character in an aqueous
     environment and provides solution phase reaction kinetics on the surface.
    ANSWER 2 OF 10 USPATFULL on STN
L9
ΑN
       2005:240469 USPATFULL
ΤI
       Stimuli-responsive hydrogel microdomes integrated with genetically
       engineered proteins for high-throughput screening of pharmaceuticals
ΙN
      Daunert, Sylvia, Lexington, KY, UNITED STATES
       Deo, Sapna Kamlakar, Lexington, KY, UNITED STATES
      Ehrick, Jason Douglas, Lexington, KY, UNITED STATES
      Browning, Tyler William, Lexington, KY, UNITED STATES
      Bachas, Leonidas G., Lexington, KY, UNITED STATES
PΙ
       US 2005208469
                          A1
                               20050922
AΙ
      US 2004-996068
                          A1
                               20041124 (10)
RLI
      Continuation-in-part of Ser. No. US 2001-905041, filed on 13 Jul 2001,
      PENDING
PRAI
      US 2000-218036P
                           20000713 (60)
DT
      Utility
FS
      APPLICATION
LREP
      MCDERMOTT WILL & EMERY LLP, 600 13TH STREET, N.W., WASHINGTON, DC,
       20005-3096, US
CLMN
      Number of Claims: 28
ECL
      Exemplary Claim: 1
DRWN
      12 Drawing Page(s)
```

LN.CNT 1453

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A hydrogel microdome that can swell in response to a stimuli or target molecule is formed by polymerizing a mixture comprising a monomer capable of forming a hydrogel with a biopolymer. An array of hydrogel microdomes can be formed on a substrate by microspotting the mixture and polymerizing. The array can be used for high-throughput screening of analytes as well as for use as an actuator and biosensor using the swelling property of the hydrogel.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ANSWER 3 OF 10 USPATFULL on STN
L9
AN
       2005:88327 USPATFULL
TI
       Programmable and autonomous computing machine made of biomolecules
TN
       Shapiro, Ehud, House #33, Nataf, ISRAEL 90804
       Benenson, Yaakov, Tel Aviv, ISRAEL
       Adar, Rivka, Carmei Yosef, ISRAEL
       Paz-Elizur, Tamar, Rehovot, ISRAEL
PΙ
       US 2005075792
                          A1
                               20050407
AΙ
       US 2004-493304
                          A1
                               20040503 (10)
       WO 2002-IL915
                               20021114
       US 2001-331318P
PRAI
                           20011114 (60)
       US 2002-386418P
                           20020607 (60)
DΤ
       Utility
FS
       APPLICATION
LREP
       Anthony Castorina, G E Ehrlich, Suite 207, 2001 Jefferson Davis Highway,
       Arlington, VA, 22202
       Number of Claims: 49
CLMN
ECL
       Exemplary Claim: 1
       11 Drawing Page(s)
DRWN
LN.CNT 1436
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A device, system and method for molecular computing which not only
       includes a suitable, renewable power source, but actually is able to
       receive power through the performance of the computations themselves.
```

AB A device, system and method for molecular computing which not only includes a suitable, renewable power source, but actually is able to receive power through the performance of the computations themselves. The molecular computing machine of the present invention actually employs the free-energy difference between its input and output to accomplish a computation, preferably by using its input DNA molecule as a partial source of energy, or alternatively by using the input DNA molecule as the sole source of energy. This molecular finite automaton preferably transforms an input DNA molecule into an output DNA molecule by digesting the input as it computes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
L9
     ANSWER 4 OF 10 USPATFULL on STN
AN
       2004:76228 USPATFULL
ΤI
       High affinity nanoparticles
       Barry, Stephen E., Oakland, CA, UNITED STATES
TN
       Soane, David S., Piedmont, CA, UNITED STATES
PA
       Alnis BioSciences, Inc. (U.S. corporation)
PΙ
       US 2004058006
                          Α1
                               20040325
AΙ
       US 2003-667635
                          A1
                               20030922 (10)
RT.T
       Continuation-in-part of Ser. No. US 2001-809340, filed on 14 Mar 2001,
       ABANDONED Continuation-in-part of Ser. No. US 2001-55837, filed on 26
       Oct 2001, PENDING Continuation of Ser. No. US 1998-172921, filed on 14
       Oct 1998, ABANDONED
PRAI
       US 2000-189625P
                           20000314 (60)
       US 1997-61805P
                           19971014 (60)
       US 1998-103616P
                           19981009 (60)
DT
       Utility
FS
       APPLICATION
LREP
       JACQUELINE S LARSON, P O BOX 2426, SANTA CLARA, CA, 95055-2426
```

CLMN Number of Claims: 16 ECL Exemplary Claim: 1 DRWN 1 Drawing Page(s) LN.CNT 1297

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

High affinity nanoparticles are provided, as well as methods for their synthesis and use. The nanoparticles of the invention comprise high affinity molecules incorporated in a polymeric nanoparticle. The high affinity nanoparticles range in size from about 1 to about 1000 nm. The high affinity molecules of the nanoparticle have moieties that have high affinity for target molecules, resulting in the ability of the high affinity nanoparticle to selectively non-covalently bind to molecular targets. The molecular recognition capability of these particles enables their use in research, diagnostic, therapeutic, and separation applications. The nanoparticles of the invention may be formed by contacting target template molecules with a set of building blocks (which includes the high affinity molecule as one subset of the building block set), which are then polymerized into a network. Removal of the templates yields a polymeric nanoparticle with three-dimensional binding sites that are complementary in shape to at least a portion of the target and including high affinity molecules chemically anchored on the surfaces of the binding sites. The high affinity nanoparticle is then capable of molecular recognition and selective binding to target molecules when presented with the target molecule in a mixture of molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 10 USPATFULL on STN AN 2004:78923 USPATFULL TΙ Microarrays and their manufacture IN Anderson, Norman G., Rockville, MD, United States Anderson, N. Leigh, Washington, DC, United States PA Large Scale Proteomics Corporation, Vacaville, CA, United States (U.S. corporation) PΙ US 6713309 20040330 US 2000-482460 ΑI 20000113 (9) PRAI US 1999-146653P 19990730 (60) DΤ Utility FS GRANTED EXNAM Primary Examiner: Chin, Christopher L. Tarcza, John E., Robbins, John C. LREP CLMN Number of Claims: 17 ECL Exemplary Claim: 1 DRWN 8 Drawing Figure(s); 8 Drawing Page(s) LN.CNT 2108

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The microarrays of the present invention are prepared by using a separate fiber for each compound being used in the microarray. The fibers are bundled and sectioned to form a thin microarray that is glued to a backing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

US 2003153001

PΙ

```
L9 ANSWER 6 OF 10 USPATFULL on STN
2003:219711 USPATFULL
TI Molecular compounds having complementary surfaces to targets
Soane, David S., Piedmont, CA, UNITED STATES
Barry, Stephen E., Oakland, CA, UNITED STATES
Goodwin, Andrew, Oakland, CA, UNITED STATES
Offord, David A., Castro Valley, CA, UNITED STATES
Perrott, Michael G., San Francisco, CA, UNITED STATES
PA Alnis, LLC (U.S. corporation)
```

20030814

A1

US 6884842 B2 20050426 AΙ US 2001-55837 **A**1 20011026 (10) Continuation of Ser. No. US 1998-172921, filed on 14 Oct 1998, ABANDONED RLI PRAI US 1997-61805P 19971014 (60) US 1998-103616P 19981009 (60) DT Utility FS APPLICATION JACQUELINE S LARSON, P O BOX 2426, SANTA CLARA, CA, 95055-2426 LREP CLMN Number of Claims: 52 ECL Exemplary Claim: 1 DRWN 29 Drawing Page(s) LN.CNT 3672 CAS INDEXING IS AVAILABLE FOR THIS PATENT. Synthetic polymer complements (SPCs) are provided, as well as methods for their synthesis and use. The SPCs may have surfaces that include functional groups that are complementary to surface sites of targets such as nanostructures or macromolecular targets, and may be capable of specifically interacting with such targets. The positions of the functional groups in one embodiment are stabilized by a polymer network. The SPCs are formed by contacting the target with a set of monomers which self-assemble on the target, and then are polymerized into a network to form the synthetic polymer complement. At least a portion of the surface of the resulting SPC thus may include an imprint of the target. The complex of the SPC and the target may be the desired product. Alternatively, the target is released, for example, by controllably expanding and contracting the crosslinked network. The SPC is isolated and used in many applications. CAS INDEXING IS AVAILABLE FOR THIS PATENT. ANSWER 7 OF 10 USPATFULL on STN L9 ΑN 2002:133444 USPATFULL ΤI Multimeric biopolymers as structural elements and sensors and actuators in microsystems TN Madou, Marc, San Diego, CA, UNITED STATES Bachas, Leonidas G., Lexington, KY, UNITED STATES Daunert, Sylvia, Lexington, KY, UNITED STATES PΙ US 2002068295 A1 20020606 ΑI US 2001-905041 Α1 20010713 (9) PRAI US 2000-218036P 20000713 (60) DTUtility FS APPLICATION CALFEE HALTER & GRISWOLD, LLP, 800 SUPERIOR AVENUE, SUITE 1400, LREP CLEVELAND, OH, 44114 CLMN Number of Claims: 42 ECL Exemplary Claim: 1 DRWN 4 Drawing Page(s) LN.CNT 939 CAS INDEXING IS AVAILABLE FOR THIS PATENT. Biomolecular complexes, hereinafter referred to a mulimeric biopolymers which can be used as the foundation of chemical control systems capable of both sensing the presence of a target analyte and actuating some mechanical response. The biomolecular complexes are multimeric biopolymers comprising at least two monomeric units. The monomeric units are selected from the group consisting of full-length proteins, polypeptides, nucleic acid molecules, and peptide nucleic acids. At least one of the monomeric units binds to the target analyte. In one highly preferred embodiment the multimeric biopolymers of the present invention undergo a detectable conformational change in response to exposure to an analyte. The present invention also provides micromachined and nanomachined devices and systems which employ the multimeric biopolymers to sense the presence of a target analyte, to actuate a response to the presence of a target analyte, or to perform

both functions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ANSWER 8 OF 10 USPATFULL on STN
L9
AN
       2001:205574 USPATFULL
ΤI
       Microarrays and their manufacture
IN
       Anderson, Norman G., Rockville, MD, United States
       Anderson, N. Leigh, Washington, DC, United States
PΙ
       US 2001041339
                         A1
                               20011115
       US 6887701
                          B2
                               20050503
ΑI
       US 2001-880019
                          A1
                               20010614 (9)
       Division of Ser. No. US 2000-482460, filed on 13 Jan 2000, PENDING
RLI
PRAI
       US 1999-146653P
                          19990730 (60)
DT
      Utility
FS
       APPLICATION
LREP
       ROYLANCE, ABRAMS, BERRO & GOODMAN, L.L.P., 1300 19TH STREET, N.W., SUITE
       600, WASHINGTON,, DC, 20036
CLMN
      Number of Claims: 50
ECL
      Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2244
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The microarrays of the present invention are prepared by using a
       separate fiber for each compound being used in the microarray. The
       fibers are bundled and sectioned to form a thin microarray that is glued
       to a backing.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 9 OF 10 USPATFULL on STN
AN
       2001:196797 USPATFULL
ΤI
       Methods and compositions for determining the sequence of nucleic acid
      molecules
IN
       Van Ness, Jeffrey, Seattle, WA, United States
       Tabone, John C., Bothell, WA, United States
       Howbert, J. Jeffry, Bellevue, WA, United States
       Mulligan, John T., Seattle, WA, United States
       Qiagen Genomics, Inc., Bothell, WA, United States (U.S. corporation)
PA
PΤ
       US 6312893.
                          В1
                               20011106
ΑI
       US 1997-898180
                               19970722 (8)
RLI
       Continuation-in-part of Ser. No. US 1997-786835, filed on 22 Jan 1997,
       now abandoned
PRAI
       US 1996-10462P
                           19960123 (60)
DТ
       Utility
EXNAM
      Primary Examiner: Houtteman, Scott W.
       Seed Intellectual Property Law Group PLLC
CLMN
      Number of Claims: 58
ECL
       Exemplary Claim: 1
       46 Drawing Figure(s); 42 Drawing Page(s)
LN.CNT 6431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       Methods and compounds, including compositions therefrom, are provided
       for determining the sequence of nucleic acid molecules. The methods
       permit the determination of multiple nucleic acid sequences
       simultaneously. The compounds are used as tags to generate tagged
       nucleic acid fragments which are complementary to a selected target
       nucleic acid molecule. Each tag is correlative with a particular
       nucleotide and, in a preferred embodiment, is detectable by mass
       spectrometry. Following separation of the tagged fragments by sequential
       length, the tags are cleaved from the tagged fragments. In a preferred
       embodiment, the tags are detected by mass spectrometry and the sequence
       of the nucleic acid molecule is determined therefrom. The individual
       steps of the methods can be used in automated format, e.g., by the
```

incorporation into systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ANSWER 10 OF 10 USPATFULL on STN
       1998:69027 USPATFULL
AN
       Method for making improved heparinized biomaterials
ΤI
IN
       Cahalan, Patrick, Geleen, Netherlands
       Lindhout, Theo, Gronsveld, Netherlands
       Fouache, Benedict, Maastricht, Netherlands
       Verhoeven, Michel, Maastricht, Netherlands
       Cahalan, Linda, Geleen, Netherlands
       Hendriks, Marc, Hoensbroek, Netherlands
       Blezer, Ron, Maastricht, Netherlands
       Medtronic, Inc., Minneapolis, MN, United States (U.S. corporation)
PA
PΙ
       US 5767108
                               19980616
ΑI
       US 1995-518147
                               19950822 (8)
DT
       Utility
       Granted
EXNAM
      Primary Examiner: Peselev, Elli
LREP
       Latham, Daniel W., Patton, Harold R.
CLMN
       Number of Claims: 5
      Exemplary Claim: 1
ECL
       1 Drawing Figure(s); 1 Drawing Page(s)
DRWN
LN.CNT 476
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A method of treating a patient with a medical device having immobilized
       heparin on a blood-contacting surface in which the covalently attached
       heparinized surface is provided with an adsorbed protein which may be
       activated by the immobilized heparin to block the coagulation of
       fibrinogen. Antithrombin III is the preferred adsorbed protein. The
       adsorbed protein is maintained on the immobilized heparin surface until
       the medical device is placed into contact with the patient's blood. When
       in contact with the patient's blood, the adsorbed protein will prevent
```

initial thrombin formation at the biomaterial-blood interface. The preadsorption of ATIII is accomplished under conditions advantageous to maximum heparin/ATIII binding. When the preadsorbed surface comes in

contact with whole blood, the maximum advantage of prophlactic

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

properties of ATIII/heparin are obtained.